Full-Life Technologies to Present at the 38th Annual Congress of the European Association of Nuclear Medicine

Shanghai, China, and Gembloux, Belgium – September 25, 2025 – Full-Life Technologies ("Full-Life", the "Company"), a fully integrated clinical-stage global radiotherapeutics company, today announced its participation in the 38th Annual Congress of the European Association of Nuclear Medicine ("EANM"), taking place in Barcelona, Spain from October 4 to 8, 2025. The Company has been selected to deliver two Top-Rated Oral Presentations ("TROP") based on accepted abstracts. In addition, the Company will host an exhibition booth, and an e-poster will be displayed at the congress.

Details of these activities are given in the table below:

Abstract Title	Detail Information
A First-in-human, Phase 1 Dose Escalation and Expansion Study Evaluating the Safety, Tolerability, and Anti-tumor Activity of [225Ac]Ac-FL-020, an Anti-PSMA Radioconjugate in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)	**Abstract ID:** OP-670 **Session Type**: Oral Presentation **Session:** Theranostics Track - Top Rated Oral Presentation Session - Oncology & Theranostics **Session Date:** Tuesday, October 7, 2025 **Session Time**: 3:00 PM **Location:** Room 117
FL-802, a B7-H3-Targeting Nanobody Radioligand Precursor, Developed Using UniRDC™ Discovery Platform	**Abstract ID:** OP-763 **Session Type**: Oral Presentation **Session:** M2M Track - TROP Session - Radiopharmaceutical Sciences + Translational Molecular Imaging & Therapy **Session Date:** Wednesday, October 8, 2025 **Session Time**: 8:30 AM **Location:** Room 114
Development of FL-261 as a theranostic RDC vector for the diagnosis and treatment of c-MET overexpression cancers	**Session Number:** EP-03 **Session Title:** Preclinical and Translational Studies -> A1 Medical Preclinical -> A13 Preclinical Oncology **Session Time:** 4 – 8 October 2025 during **e-Poster Number:** EP-0035
Full-Life Booth	**#79a**

About [225Ac]Ac-FL-020

[225Ac]Ac-FL-020 is a novel, potential best-in-class, next-generation PSMA-targeting radionuclide drug conjugate (“RDC”) that entered global Ph1 clinical studies in 2024. Its targeting vector, FL-020, was discovered using Full-Life's proprietary UniRDC™ platform, which enables significant improvement of drug uptake in the tumor while maintaining fast systemic

clearance. The U.S. FDA has granted [225Ac]Ac-FL-020 Fast Track Designation. In ongoing Phase I dose escalation trial, it has demonstrated favorable safety profile.

About FL-261

FL-261 is a first-in-class radioligand therapy targeting c-MET, it demonstrates potent and selective binding to c-MET protein, high and specific tumor uptake and promising anti-tumor activities in multiple xenograft models with different levels of c-MET expression.

About FL-802

FL-802 is a first-in-class radioligand therapy targeting B7H3, it exhibits potent B7H3 binding affinity in the in vitro assays, and high and specific tumor uptake and promising tumor growth suppression efficacy in multiple xenograft mouse models.

About Full-Life Technologies

Full-Life Technologies ("Full-Life") is a fully integrated clinical-stage global radiotherapeutics company with operations in Belgium, Germany, and China. We aim to own the entire value chain for radiopharmaceutical research & development, production & commercialization to deliver clinical impact for patients. The Company endeavors to tackle fundamental challenges affecting radiopharmaceuticals today by pioneering innovative research that will shape the treatments of tomorrow. We are comprised of a team of fast-moving entrepreneurs and seasoned scientists with a proven history of success in the life sciences, alongside radioisotope research and clinical development.

Media Contacts:

Full-Life
Email: pr@t-full.com
Website: www.full-life.com